Increased expression of magnocellular vasopressin mRNA in rats with deoxycorticosterone-acetate induced salt appetite. 1998

C A Grillo, and F Saravia, and M Ferrini, and G Piroli, and P Roig, and S I García, and E R de Kloet, and A F De Nicola
Laboratory of Neuroendocrine Biochemistry, Instituto de Biologia y Medicina Experimental, University of Buenos Aires, Argentina.

The neuropeptides arginine vasopressin (AVP) and oxytocin (OT) have been implicated in the genesis of hypertension due to deoxycorticosterone acetate (DOCA)-salt treatment of uninephrectomized rats. In this work, we studied if DOCA treatment of intact rats in doses arousing a salt appetite (a prehypertensive state), modulated mRNA for AVP and OT in the hypothalamus. Male Sprague-Dawley rats were offered both tap water and 3% NaCl in separate bottles and received vehicle or subcutaneous injections of 10 mg DOCA on alternate days for 7 days (4 injections) or 17 days (9 injections). They developed a preference for 3% NaCl solutions 24-48 h after treatment. Brain slices from rats killed on the 8th or 18th day were exposed to 35S-labeled probes encoding prepro-AVP mRNA or OT mRNA, respectively. Expression of these mRNAs was measured in the magnocellular and parvocellular divisions of the paraventricular nucleus (PVN) and magnocellular cells of the supraoptic nucleus (SON). No changes were obtained in neuropeptide mRNA levels in the parvocellular division of the PVN between control and the two groups of DOCA-treated rats. However, DOCA-treated animals presented an increased number of grains per cell for AVP mRNA in the magnocellular division of the PVN and in magnocellular cells of the SON, as shown by group mean comparisons and frequency histograms. No changes were detected for OT mRNA. In a second series of studies, control or DOCA-treated rats were offered 3% NaCl or water as the only choice. Animals drinking 3% NaCl showed increased AVP and OT mRNA levels, whether they received DOCA or not. However, AVP mRNA levels in both nuclei were higher in DOCA-treated rats drinking 3% NaCl than in controls drinking salt solution. In comparison, control and DOCA-treated rats drinking water showed lower levels of AVP mRNA. OT mRNA levels in the SON remained unchanged in the same groups. The results suggest that in the magnocellular cells of the PVN and SON, increments in AVP mRNA are obtained following increments in salt intake produced by either mineralocorticoid treatment or exclusive salt drinking. In rats offered salt solution and water to drink, DOCA effects on AVP mRNA developed before changes occurred in serum sodium levels. Because combined DOCA + salt treatment induced a higher response in terms of AVP mRNA expression, we suggest that AVP could be a target of the central effects of the mineralocorticoid.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008297 Male Males
D009994 Osmolar Concentration The concentration of osmotically active particles in solution expressed in terms of osmoles of solute per liter of solution. Osmolality is expressed in terms of osmoles of solute per kilogram of solvent. Ionic Strength,Osmolality,Osmolarity,Concentration, Osmolar,Concentrations, Osmolar,Ionic Strengths,Osmolalities,Osmolar Concentrations,Osmolarities,Strength, Ionic,Strengths, Ionic
D010121 Oxytocin A nonapeptide hormone released from the neurohypophysis (PITUITARY GLAND, POSTERIOR). It differs from VASOPRESSIN by two amino acids at residues 3 and 8. Oxytocin acts on SMOOTH MUSCLE CELLS, such as causing UTERINE CONTRACTIONS and MILK EJECTION. Ocytocin,Pitocin,Syntocinon
D010286 Paraventricular Hypothalamic Nucleus Nucleus in the anterior part of the HYPOTHALAMUS. Hypothalamic Paraventricular Nucleus,Paraventricular Nucleus,Hypothalamic Nucleus, Paraventricular,Nucleus, Hypothalamic Paraventricular,Nucleus, Paraventricular,Nucleus, Paraventricular Hypothalamic,Paraventricular Nucleus, Hypothalamic
D003900 Desoxycorticosterone A steroid metabolite that is the 11-deoxy derivative of CORTICOSTERONE and the 21-hydroxy derivative of PROGESTERONE 21-Hydroxyprogesterone,Cortexone,Deoxycorticosterone,Desoxycortone,11-Decorticosterone,21-Hydroxy-4-pregnene-3,20-dione,11 Decorticosterone,21 Hydroxy 4 pregnene 3,20 dione,21 Hydroxyprogesterone
D004326 Drinking The consumption of liquids. Water Consumption,Water Intake,Drinkings
D000311 Adrenal Glands A pair of glands located at the cranial pole of each of the two KIDNEYS. Each adrenal gland is composed of two distinct endocrine tissues with separate embryonic origins, the ADRENAL CORTEX producing STEROIDS and the ADRENAL MEDULLA producing NEUROTRANSMITTERS. Adrenal Gland,Gland, Adrenal,Glands, Adrenal
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001066 Appetite Natural recurring desire for food. Alterations may be induced by APPETITE DEPRESSANTS or APPETITE STIMULANTS. Appetite Alterations,Alteration, Appetite,Alterations, Appetite,Appetite Alteration,Appetites

Related Publications

C A Grillo, and F Saravia, and M Ferrini, and G Piroli, and P Roig, and S I García, and E R de Kloet, and A F De Nicola
December 2001, Neuroendocrinology,
C A Grillo, and F Saravia, and M Ferrini, and G Piroli, and P Roig, and S I García, and E R de Kloet, and A F De Nicola
January 1998, Life sciences,
C A Grillo, and F Saravia, and M Ferrini, and G Piroli, and P Roig, and S I García, and E R de Kloet, and A F De Nicola
November 1999, Journal of the American Society of Nephrology : JASN,
C A Grillo, and F Saravia, and M Ferrini, and G Piroli, and P Roig, and S I García, and E R de Kloet, and A F De Nicola
May 1998, Clinical science (London, England : 1979),
C A Grillo, and F Saravia, and M Ferrini, and G Piroli, and P Roig, and S I García, and E R de Kloet, and A F De Nicola
October 1992, Hypertension (Dallas, Tex. : 1979),
C A Grillo, and F Saravia, and M Ferrini, and G Piroli, and P Roig, and S I García, and E R de Kloet, and A F De Nicola
November 2000, Journal of cardiovascular pharmacology,
C A Grillo, and F Saravia, and M Ferrini, and G Piroli, and P Roig, and S I García, and E R de Kloet, and A F De Nicola
June 1993, Hypertension (Dallas, Tex. : 1979),
C A Grillo, and F Saravia, and M Ferrini, and G Piroli, and P Roig, and S I García, and E R de Kloet, and A F De Nicola
April 1985, Endocrinology,
C A Grillo, and F Saravia, and M Ferrini, and G Piroli, and P Roig, and S I García, and E R de Kloet, and A F De Nicola
October 1996, The American journal of physiology,
C A Grillo, and F Saravia, and M Ferrini, and G Piroli, and P Roig, and S I García, and E R de Kloet, and A F De Nicola
October 1993, Physiology & behavior,
Copied contents to your clipboard!